3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started

3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started
·4 min read

Pfizer (NYSE: PFE) is expecting its coronavirus vaccine to generate a whopping $33.5 billion in revenue this year. Rival Moderna (NASDAQ: MRNA) is likely to offer an update on its vaccine during its quarterly earnings report on Thursday. During the last report, Moderna said advance purchase agreements for the year represented more than $19 billion in product sales.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting